Zura Bio stops hidradenitis suppurativa program after phase‑2 miss
+4 new sources since this summary was written
Zura Bio announced that its phase‑2 TibuSHIELD study of tibulizumab in adults with moderate‑to‑severe hidradenitis suppurativa failed to achieve the primary endpoint and key secondary endpoints. The trial enrolled 247 patients and showed lesion‑count reductions of 56.0% and 58.1% for the 300 mg and 150 mg doses, compared with 52.5% for placebo. The company will discontinue development for this indication but will keep its systemic‑sclerosis and polymyalgia‑rheumatica programs alive.
Why it matters
The halt removes a potential revenue stream and may pressure the share price, as reflected by a 68%‑plus drop in trading. Zura still has $187.7 million in cash, which it expects to fund operations through at least the end of 2028, so the cash runway remains unchanged.
Key facts
- 1The phase‑2 trial enrolled 247 adults with moderate‑to‑severe hidradenitis suppurativa. investing.com
- 2Lesion‑count reductions were 56.0% for the 300 mg dose and 58.1% for the 150 mg dose, versus 52.5% for placebo. investing.com
- 3The study did not meet its primary endpoint of a statistically significant difference in total abscess and inflammatory nodule count change at week 16. investing.com
- 4Key secondary endpoints (HiSCR50, HiSCR75) were also not met. investing.com
- 5Zura will discontinue tibulizumab development for hidradenitis suppurativa but will continue the TibuSURE trial in systemic sclerosis and the NEXUS‑PMR trial in polymyalgia rheumatica. investing.com
- 6Cash and cash equivalents were $187.7 million as of September 30 2026, expected to fund operations through at least the end of 2028. investing.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.